The strong beat, first GAAP profitable quarter, raised guidance, and accelerating operational metrics (Oncology volume, MRD, Insights) are clear positives. The ~$1.5B Personalis acquisition adds a leading MRD technology but introduces integration risk and near-term dilution. Monitor the Q3 2026 call for updates on Personalis deal closure (expected late Q4 2026/early 2027) and any changes to the ~$65M Adjusted EBITDA guidance.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $43.87entry
- T+1 · 4mo ago +4.97%α +3.54% · $46.05
- T+5 · 3mo ago +18.65%α +15.13% · $52.05
- T+20 · 3mo ago +45.98%α +42.99% · $64.04
- T+60 · 22d ago +53.09%α +50.63% · $67.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tempus AI reported Q2 2026 revenue of $382.5M (+22% YoY), beating consensus of $379.5M, and a non-GAAP net loss per share of -$0.04, beating the consensus estimate of -$0.15. The company achieved its first GAAP net income quarter ($5.6M), generated positive Adjusted EBITDA of $8.0M, and raised full-year revenue guidance to $1.595-$1.605B. The quarter was highlighted by strong operational metrics including 31% oncology volume growth, 36% Insights revenue growth, and ~$200M in new Data & Applications bookings, alongside the announced acquisition of Personalis for ~$1.5B.
Key Financial Metrics
Key Facts
- Total revenue of $382.5M, up 22% YoY, beating consensus of $379.5M.
- Non-GAAP net loss per share of -$0.04, beating consensus estimate of -$0.15 (73.6% beat).
- First GAAP net income quarter of $5.6M, compared to a net loss of -$42.8M in Q2 2025.
- Adjusted EBITDA of $8.0M, compared to -$5.6M in Q2 2025.
- Raised full-year 2026 revenue guidance to $1.595-$1.605 billion (~25% annual growth).
- Oncology volume grew 31% YoY; MRD volume reached 9,000 tests (up from 6,500 last quarter).
- Data Licensing & Modeling (Insights) revenue grew 36% YoY; signed ~$200M in new Data & Applications licenses.
- Announced definitive agreement to acquire Personalis for ~$1.5B enterprise value.
- Completed a $460M offering of 0.0% convertible senior notes due 2032; cash and marketable securities of $820.7M.
Financial Impact
Revenue beat consensus by ~$3M; EPS beat by ~$0.11. Raised FY2026 revenue guidance by $5M at the midpoint. The ~$1.5B Personalis acquisition represents a significant strategic investment.
Risk Factors
- Integration risk and potential dilution from the ~$1.5B Personalis acquisition.
- Operating cash flow remains negative (-$80.8M in H1 2026), though improving.
- Revenue growth decelerated to 22% YoY from 36% YoY in Q1 2026, partly due to the Ambry acquisition anniversary.
- GAAP net income was driven by $98.5M in unrealized gains on marketable securities, which is non-recurring.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-326083 |
| Document: tem-20260730.htm | 0001193125-26-326083 |
| Document: 0001193125-26-326083-index-headers.html | 0001193125-26-326083 |
| Document: 0001193125-26-326083-index.html | 0001193125-26-326083 |
| Document: 0001193125-26-326083.txt | 0001193125-26-326083 |
| 8-K Data (Synthetic) | 0001193125-26-326083 |
Track record
45 reports on TEM
7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +40.92% at T+60 after the Jul 20, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $78.48 Now $64.76 −17.48% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers